IDEXX Laboratories (NASDAQ:IDXX) EVP George Fennell Sells 11,345 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

IDEXX Laboratories Stock Up 0.3%

IDXX traded up $2.20 during trading on Wednesday, reaching $648.73. 400,128 shares of the stock traded hands, compared to its average volume of 516,144. The stock has a market cap of $51.80 billion, a price-to-earnings ratio of 49.64, a price-to-earnings-growth ratio of 3.89 and a beta of 1.67. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The stock’s 50-day simple moving average is $690.23 and its two-hundred day simple moving average is $667.06.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the firm posted $2.53 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on IDXX shares. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, Morgan Stanley boosted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blalock Williams LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $590,000. New York State Common Retirement Fund raised its stake in shares of IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Arkadios Wealth Advisors bought a new position in IDEXX Laboratories in the second quarter worth $405,000. Mediolanum International Funds Ltd lifted its position in IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after purchasing an additional 4,909 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.